Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yi-Zhi-An-Shen Granules for aMCI
NCT03601000Phase 2Completed
- Sponsor
- Chengdu University of Traditional Chinese Medicine
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amnestic mild cognitive impairment (MCI) comparing Yi-Zhi-An-Shen with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 22 months. Started Apr 2018; status: completed.
02
Drugs
Yizhi Anshen
03
Conditions
amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT03601000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601000.